Milestones and Ambition: Cybrexa’s Vision for 2024

As I look back on my inaugural year at Cybrexa, the significant growth and development is undeniable. The expansion of our team, marked by the addition of key leadership members, brought a wealth of operational, therapeutic, clinical, and regulatory expertise to the forefront. These appointments are pivotal as we advance our lead candidate, a tumor-targeting peptide drug conjugate (PDC), transitioning it from Phase I into Phase II clinical trials.

The initial clinical findings for our lead candidate are promising, having established potent anti-tumor activity and efficacy with manageable toxicity. These accomplishments pave the way for Phase II clinical trials in colon, lung, breast, and ovarian cancers in 2024; a milestone that demonstrates progress, instills confidence, and strengthens our commitment to advancing Cybrexa’s alphalex™ technology, a novel antigen-independent PDC platform. Furthermore, this success offers optimism to the promise of our other pre-clinical candidates.

At Cybrexa, we attribute our success to the vitality of our team culture, which is the cornerstone of our company. Our commitment to maintaining a dynamic, collaborative, and transparent environment ensures that we work together seamlessly towards common goals. Guided by the leadership of our CEO, Per Hellsund , we strive to embrace a culture that thrives on trust, speed, and flexibility which inspires us to achieve our highest potential. This passion extends beyond our internal ambition; it’s a promise to the patients whose lives we aim to impact and to the communities in which we serve.

Looking towards 2024, we have set ambitious goals for ourselves. I am encouraged by the progress and excited by the momentum our small team has created. As we embark on this exciting next chapter, we welcome you to follow Cybrexa’s journey. Our alphalex™ technology is a first-in-class innovation with vast possibilities and the potential to positively impact the landscape of cancer treatment.

#WeAreCybrexa #PeptideDrugConjugates #Oncology #CancerResearch #ClinicalTrials #NewHaven #Biotech #SmallMolecules